-
Something wrong with this record ?
Ivabradine Ameliorates Kidney Fibrosis in L-NAME-Induced Hypertension
P. Stanko, T. Baka, K. Repova, S. Aziriova, K. Krajcirovicova, A. Barta, P. Janega, M. Adamcova, L. Paulis, F. Simko,
Language English Country Switzerland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2014
Free Medical Journals
from 2014
PubMed Central
from 2014
Europe PubMed Central
from 2014
Open Access Digital Library
from 2014-01-01
Open Access Digital Library
from 2014-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2014
- Publication type
- Journal Article MeSH
Hypertension-induced renal injury is characterized by structural kidney alterations and function deterioration. Therapeutics for kidney protection are limited, thus novel renoprotectives in hypertension are being continuously sought out. Ivabradine, an inhibitor of the If current in the sinoatrial node reducing heart rate (HR), was shown to be of benefit in various cardiovascular pathologies. Yet, data regarding potential renoprotection by ivabradine in hypertension are sparse. Thirty-six adult male Wistar rats were divided into non-diseased controls and rats with NG-nitro-L-arginine methyl ester (L-NAME)-induced hypertension to assess ivabradine's site-specific effect on kidney fibrosis. After 4 weeks of treatment, L-NAME increased the average systolic blood pressure (SBP) (by 27%), decreased glomerular density (by 28%) and increased glomerular tuft area (by 44%). Moreover, L-NAME induced glomerular, tubulointerstitial, and vascular/perivascular fibrosis by enhancing type I collagen volume (16-, 19- and 25-fold, respectively). L-NAME also increased the glomerular type IV collagen volume and the tubular injury score (3- and 8-fold, respectively). Ivabradine decreased average SBP and HR (by 8 and 12%, respectively), increased glomerular density (by 57%) and reduced glomerular tuft area (by 30%). Importantly, ivabradine decreased type I collagen volume at all three of the investigated sites (by 33, 38, and 72%, respectively) and enhanced vascular/perivascular type III collagen volume (by 67%). Furthermore, ivabradine decreased the glomerular type IV collagen volume and the tubular injury score (by 63 and 34%, respectively). We conclude that ivabradine attenuated the alterations of glomerular density and tuft area and modified renal fibrosis in a site-specific manner in L-NAME-hypertension. It is suggested that ivabradine may be renoprotective in hypertensive kidney disease.
Department of Physiology School of Medicine Charles University Prague Czechia
Institute of Pathophysiology Faculty of Medicine Comenius University Bratislava Slovakia
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20021988
- 003
- CZ-PrNML
- 005
- 20201204093515.0
- 007
- ta
- 008
- 201125s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fmed.2020.00325 $2 doi
- 035 __
- $a (PubMed)32754607
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Stanko, Peter $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
- 245 10
- $a Ivabradine Ameliorates Kidney Fibrosis in L-NAME-Induced Hypertension / $c P. Stanko, T. Baka, K. Repova, S. Aziriova, K. Krajcirovicova, A. Barta, P. Janega, M. Adamcova, L. Paulis, F. Simko,
- 520 9_
- $a Hypertension-induced renal injury is characterized by structural kidney alterations and function deterioration. Therapeutics for kidney protection are limited, thus novel renoprotectives in hypertension are being continuously sought out. Ivabradine, an inhibitor of the If current in the sinoatrial node reducing heart rate (HR), was shown to be of benefit in various cardiovascular pathologies. Yet, data regarding potential renoprotection by ivabradine in hypertension are sparse. Thirty-six adult male Wistar rats were divided into non-diseased controls and rats with NG-nitro-L-arginine methyl ester (L-NAME)-induced hypertension to assess ivabradine's site-specific effect on kidney fibrosis. After 4 weeks of treatment, L-NAME increased the average systolic blood pressure (SBP) (by 27%), decreased glomerular density (by 28%) and increased glomerular tuft area (by 44%). Moreover, L-NAME induced glomerular, tubulointerstitial, and vascular/perivascular fibrosis by enhancing type I collagen volume (16-, 19- and 25-fold, respectively). L-NAME also increased the glomerular type IV collagen volume and the tubular injury score (3- and 8-fold, respectively). Ivabradine decreased average SBP and HR (by 8 and 12%, respectively), increased glomerular density (by 57%) and reduced glomerular tuft area (by 30%). Importantly, ivabradine decreased type I collagen volume at all three of the investigated sites (by 33, 38, and 72%, respectively) and enhanced vascular/perivascular type III collagen volume (by 67%). Furthermore, ivabradine decreased the glomerular type IV collagen volume and the tubular injury score (by 63 and 34%, respectively). We conclude that ivabradine attenuated the alterations of glomerular density and tuft area and modified renal fibrosis in a site-specific manner in L-NAME-hypertension. It is suggested that ivabradine may be renoprotective in hypertensive kidney disease.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Baka, Tomas $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
- 700 1_
- $a Repova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
- 700 1_
- $a Aziriova, Silvia $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
- 700 1_
- $a Krajcirovicova, Kristina $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
- 700 1_
- $a Barta, Andrej $u Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia.
- 700 1_
- $a Janega, Pavol $u Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia. Institute of Pathological Anatomy, Faculty of Medicine, Comenius University, Bratislava, Slovakia.
- 700 1_
- $a Adamcova, Michaela $u Department of Physiology, School of Medicine, Charles University, Prague, Czechia.
- 700 1_
- $a Paulis, Ludovit $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia.
- 700 1_
- $a Simko, Fedor $u Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovakia. 3rd Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia. Institute of Experimental Endocrinology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.
- 773 0_
- $w MED00188756 $t Frontiers in medicine $x 2296-858X $g Roč. 7, č. - (2020), s. 325
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32754607 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201204093512 $b ABA008
- 999 __
- $a ind $b bmc $g 1591696 $s 1112660
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 7 $c - $d 325 $e 20200710 $i 2296-858X $m Frontiers in medicine $n Front. med. $x MED00188756
- LZP __
- $a Pubmed-20201125